Anatomic Pathology Market

The anatomic pathology market is projected to grow from USD 8.9 billion in 2026 to USD 14.5 billion in 2031, at a CAGR of 10.2% during the forecast period. The growing global burden of cancer and other chronic diseases, which require tissue-based diagnoses for accurate disease characterization and treatment planning, has highlighted the importance of histopathology and cytopathology in clinical practice. There is an increasing demand for early disease detection and precision medicine, which has further reinforced this need.

Advancements in automation, digital pathology, artificial intelligence, and image analysis technologies are transforming pathology workflows by enhancing diagnostic accuracy, improving laboratory efficiency, and enabling remote consultations. Furthermore, increasing investments in laboratory modernization, a greater adoption of biomarker-driven testing, and the expansion of healthcare infrastructure are supporting market growth.

To know about the assumptions considered for the study download the pdf brochure

Emerging economies in the Asia Pacific, Latin America, and the Middle East & Africa offer significant growth opportunities due to improving access to cancer diagnostics, rising healthcare expenditures, and the ongoing development of pathology laboratory networks. Key companies in this field, including F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies, Inc. (US), and Hologic, Inc. (US), have implemented various growth strategies, both organic and inorganic. These strategies include product launches, the development of AI-integrated platforms, innovations in digital pathology, and targeted acquisitions and partnerships.

For example, in May 2026, Roche announced its acquisition of PathAI, a provider of digital pathology and artificial intelligence technologies. This acquisition enhances Roche’s digital pathology capabilities by integrating advanced AI-powered image analysis solutions and improving its companion diagnostics and precision oncology offerings.

Similarly, in January 2024, Epredia, a subsidiary of PHC Holdings Corporation, launched the SlideMate Laser Printer, a pathology slide printing solution designed to enhance specimen traceability, improve laboratory workflow efficiency, and increase diagnostic accuracy in anatomic pathology laboratories.

F. Hoffmann-La Roche Ltd. is a leading player in the anatomic pathology market, supported by its strong anatomic pathology portfolio and extensive global presence. Roche offers a broad range of solutions for histopathology and cytopathology applications through its VENTANA portfolio, which supports cancer diagnostics using immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and companion diagnostic technologies. For instance, the VENTANA BenchMark ULTRA platform enables automated tissue staining and biomarker analysis, while the VENTANA DP 600 digital pathology scanner supports high-throughput slide digitization and image management workflows within pathology laboratories. Additionally, Roche strengthens its competitive position through digital pathology solutions such as the navify Digital Pathology platform, which enables centralized image management, AI-assisted analysis, and remote pathology collaboration across healthcare networks. Roche continues to enhance its innovation capabilities and maintain a strong position in the global anatomic pathology market.

Danaher Corporation has strengthened its position in the anatomic pathology market through its extensive diagnostics portfolio. Danaher serves a broad range of customers, including hospital pathology laboratories, cancer centers, academic medical institutions, and specialized diagnostic facilities worldwide. The company’s leadership is supported by innovative anatomic pathology solutions such as Leica Biosystems’ BOND RX and BOND-III systems, which enable automated immunohistochemistry (IHC) and in situ hybridization (ISH) testing, as well as the Aperio GT 450 DX digital pathology scanner, which supports high-throughput slide digitization and digital pathology workflows. In addition, Danaher continues to advance precision oncology through its diagnostics capabilities and AI-enabled pathology solutions, helping improve laboratory efficiency, diagnostic accuracy, and workflow standardization. Through continuous innovation and strategic investments, Danaher continues to strengthen its competitive position and expand its presence across the global anatomic pathology market.

Market Ranking

F. Hoffmann-La Roche Ltd. has emerged as a leading participant in the anatomic pathology market owing to its comprehensive portfolio of immunohistochemistry (IHC), in situ hybridization (ISH), and digital pathology solutions. The company’s leadership is further strengthened by its advanced staining platforms, digital pathology ecosystem, AI-enabled image analysis capabilities, and strong global presence across pathology laboratories and cancer centers worldwide.

Danaher Corporation has strengthened its position in the market through its extensive diagnostics portfolio, particularly through Leica Biosystems, which offers a broad range of tissue processing, staining, digital pathology, and workflow automation solutions. The company's leadership is supported by innovative platforms enabling pathology laboratories to improve efficiency, standardization, and diagnostic accuracy.

PHC Holdings Corporation (Epredia) has established a strong presence in the market through its comprehensive portfolio of histology and cytology solutions used across tissue preparation, sectioning, staining, and slide management workflows. The company’s leadership is supported by products such as microtomes, tissue processors, slide printers, and staining systems that enhance laboratory productivity, specimen traceability, and diagnostic workflow efficiency in pathology laboratories worldwide.

Agilent Technologies, Inc. maintains a strong market position through its integrated tissue diagnostics portfolio comprising antibodies, reagents, automated staining platforms, companion diagnostics, and biomarker testing solutions. Through its Dako product portfolio and continued investments in pathology innovation, Agilent supports advanced cancer diagnostics and precision medicine applications across clinical and research pathology settings.

Hologic, Inc. is another important contributor to the market through its cytopathology and cervical cancer screening portfolio. The company’s advanced cytology platforms combine automated sample preparation, digital imaging, and AI-assisted review capabilities, helping pathology laboratories improve screening efficiency, workflow productivity, and diagnostic confidence.

Together, these companies continue to strengthen their market positions through product innovation, technological advancements, strategic investments, and expansion of their anatomic pathology capabilities, contributing to the growth and development of the global anatomic pathology market.

Related Reports:

Anatomic Pathology Market by Product [Consumables (Histopathology, Cytopathology), Instruments, Software], Process, Disease (Breast, GI, Prostate), End User (Hospitals, Research Labs), Services, Model (In House, Outsourced) – Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]